Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/12/2026 | $27.00 | Outperform → Neutral | Daiwa Securities | |
| 2/5/2026 | $400.00 → $420.00 | Buy | Pivotal Research Group | |
| 1/29/2026 | Equal Weight → Overweight | Barclays | ||
| 1/22/2026 | $400.00 | Outperform → Strong Buy | Raymond James | |
| 1/15/2026 | Outperform | RBC Capital Mkts | ||
| 1/13/2026 | $350.00 → $355.00 | Buy | TD Cowen | |
| 1/9/2026 | $94.00 | Buy | Goldman | |
| 1/7/2026 | $330.00 → $390.00 | Buy | Canaccord Genuity |
4 - Ventas, Inc. (0000740260) (Issuer)
4 - Ventas, Inc. (0000740260) (Issuer)
4 - Ventas, Inc. (0000740260) (Issuer)
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment. LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment prac
Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMPAVZI would become the first non-factor prophylactic treatment available for children aged 6 to 11 years with hemophilia B Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patient
8-K - Ventas, Inc. (0000740260) (Filer)
424B5 - Ventas, Inc. (0000740260) (Filer)
10-K - Ventas, Inc. (0000740260) (Filer)
Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00
Pivotal Research Group reiterated coverage of Alphabet with a rating of Buy and set a new price target of $420.00 from $400.00 previously
Barclays upgraded ASML from Equal Weight to Overweight
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
ASML appoints next Chief Technology Officer Marco Pieters appointed ASML Chief Technology Officer ASML Supervisory Board intends to reappoint CFO Roger Dassen and COO Frédéric Schneider-Maunoury, and to appoint CTO Marco Pieters to the Board of Management as of the April 2026 AGM VELDHOVEN, The Netherlands, October 9, 2025 – ASML Holding NV (ASML) today announced the appointment of Marco Pieters as Executive Vice President and Chief Technology Officer, reporting to President and Chief Executive Officer, Christophe Fouquet. With over 25 years of experience at ASML, most recently as Executive Vice President for the product area Applications, Pieters has a strong track record in technology l
Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T
Ventas, Inc. (NYSE:VTR) ("Ventas" or the "Company") today reported results for the full year and fourth quarter ended December 31, 2025. CEO Remarks "Ventas delivered strong performance and enterprise growth in the fourth quarter and full year 2025. We executed our strategy to drive organic and external growth in senior housing and increased our participation in this multiyear growth opportunity," said Debra A. Cafaro, Ventas Chairman and CEO. "In 2025, we grew Same-Store Cash Net Operating Income ("NOI") by over 15% in our senior housing operating portfolio ("SHOP"). We capitalized on powerful secular demand trends and utilized our proprietary analytic and operational insights to del
Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc
ASML reports €32.7 billion total net sales and €9.6 billion net income in 2025ASML expects 2026 total net sales to be between €34 billion and €39 billion, with a gross margin between 51% and 53% VELDHOVEN, the Netherlands, January 28, 2026 – Today, ASML Holding NV (ASML) has published its 2025 fourth-quarter and full-year results. Q4 total net sales of €9.7 billion, gross margin of 52.2%, net income of €2.8 billionQuarterly net bookings in Q4 of €13.2 billion of which €7.4 billion is EUV2025 total net sales of €32.7 billion, gross margin of 52.8%, net income of €9.6 billionBacklog at the end of 2025 of €38.8 billionASML expects Q1 2026 total net sales between €8.2 billion and €8.9 billion
SC 13G - Ventas, Inc. (0000740260) (Subject)
SC 13G/A - Ventas, Inc. (0000740260) (Subject)
SC 13G - Ventas, Inc. (0000740260) (Subject)